SCHEMBL20738474

SCHEMBL20738474

CCc1ccc(Cc2cccs2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
POLB P06746 2/20 0.47
TRPM8 Q7Z2W7 1/20 0.44
GAA P10253 2/20 0.43
PTGS1 P23219 2/20 0.43
PTGS2 P35354 2/20 0.43
TP53 P04637 2/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
LTA4H P09960 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385419 0.83 MEN1 (0.54) MEN1KMT2APOLBTRPM8GAA
SCHEMBL45228 0.80 LMNA (0.50) POLBPTGS1PTGS2NPC1RAB9A
SCHEMBL10525378 0.79 L3MBTL1 (0.55) MEN1KMT2APTGS1PTGS2TAAR1
Methyl Alcohol SCHEMBL5311361 0.79 LMNA (0.50) MEN1KMT2APOLBPTGS1PTGS2
SCHEMBL3238290 0.79 LMNA (0.62) MEN1KMT2APOLBPTGS1PTGS2
SCHEMBL10953000 0.79 HPGD (0.46) MEN1KMT2APOLBTRPM8PTGS1
SCHEMBL7294757 0.79 CYP3A4 (0.52) MEN1KMT2APOLBPTGS1PTGS2
SCHEMBL11660485 0.79 TAAR1 (0.42) MEN1KMT2APTGS1PTGS2TAAR1
SCHEMBL29337530 0.79 LTA4H (0.57) MEN1KMT2APOLBPTGS1PTGS2
SCHEMBL923302 0.79 MEN1 (0.53) MEN1KMT2APOLBNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed
CN-103214471-B The preparation method of compound with Na-dependent glucose transporter inhibitory activity 田边三菱制药株式会社 2018-02-06 CN disclosed
CN-104109155-A Novel compounds TANABE SEIYAKU CO 2014-10-22 CN disclosed
CN-103819465-A Novel compound MITSUBISHI TANABE PHARMA CORP 2014-05-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 MEN1 1644/4885KMT2A 968/4885POLB 2980/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 MEN1 1644/4885KMT2A 968/4885POLB 2980/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 MEN1 1644/4885KMT2A 968/4885POLB 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.